It is an antihistimine drug, with neuroprotective properties and also
potential nootropic properties.
It has been used clinically in Russia since 1983 (according to Wikipedia).
(Premature cell death and poor mito function both very much implicated in
M.E.)
Their site says:
"Dimebon is an orally-available, small molecule that has been shown to
inhibit brain cell death in preclinical models relevant to Alzheimer's
disease and Huntington's disease, making it a potential treatment for these
and other neurodegenerative diseases. Based on clinical and preclinical data
generated to date, Medivation believes that Dimebon works through a novel
mechanism of action improving mitochondria function.
We are currently evaluating Dimebon in clinical trials for both Alzheimer's
disease and Huntington's diseases."
http://www.medivation.com/pipeline_dimebon.html
Best wishes,
Jodi Bassett
--
The Hummingbirds' Foundation
for Myalgic Encephalomyelitis:
www.hfme.org
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
